FDA decides against Lipitor-Zetia combo
The FDA rejected an application to market cholesterol drugs Lipitor and Zetia as a combination treatment because of a lack of manufacturing and stability data. Merck & Co., which developed Zetia with Schering-Plough, said it is reviewing the complete-response letter "to determine a new timetable for filing."
Wall Street Journal, The | 11/02
This story published in FDLI SmartBrief on 11/03/2009
More from SmartBrief:
Merck, Schering to pay $41.5M settlement over Zetia, Vytorin
Thursday, August 6, 2009
Zetia, Vytorin makers to pay legal costs of marketing investigations
Thursday, July 16, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|